Latest Breaking News On - பீட்டர் குலிக் - Page 5 : comparemela.com

email article Now that Johnson & Johnson has joined Pfizer and Moderna in having a COVID-19 vaccine authorized in the U.S., the question on many people s minds is: who gets which vaccine? Much of the discussion has focused on the differing vaccine efficacy numbers for the three products: those given for the J&J vaccine are in the 70% range, versus more than 90% for Pfizer s and Moderna s. But the Biden administration and independent public health specialists insist that those figures aren t strictly comparable and the public shouldn t pay much attention to them. Johnson & Johnson s is not an inferior vaccine, and we should not talk about who shouldn t get it; we should talk about how we can immunize hard-to-get populations, said Sarah Long, MD, a pediatric diseases physician at Drexel University College of Medicine in Philadelphia and a member of the CDC s Advisory Committee on Immunization Practices (ACIP), during an emergency meeting of the committee Monday.

United statesNew yorkWhite houseDistrict of columbiaSouth africaDrexel universityMeera mehtaSonja hutchinsAnthony fauciKyle fergusonPeter gulickArthur caplanHemi tewarsonSarah longChris martinMarcella nunez smith